Aria Diagnostics said this week that it has changed its name to Ariosa Diagnostics "to further distinguish and differentiate itself from other companies and products."
The company also said it has completed a clinical validation study for its Harmony Prenatal Test, a non-invasive test for common fetal trisomies. The test analyzes cell-free fetal DNA from maternal blood using targeted sequencing.
Ariosa plans to present more details on its test technology and data analysis at the American College of Medical Genetics annual meeting in Charlotte, NC, this week.
"The completion of our validation study is an important milestone as we prepare to bring the Harmony Prenatal Test to market," said Ken Song, Ariosa's CEO, in a statement. He said that the study results support the company's previous findings of highly accurate fetal trisomy detection, which were published in January in two medical journals — the American Journal of Obstetrics and Gynecology and Prenatal Diagnosis (CSN 2/1/2012).
Also in January, the company said that it plans to launch the test in the US in the first half of this year for under $1,000 (CSN 1/18/2012).
Ariosa is in litigation with Sequenom, which already has a similar test called MaterniT21 on the market. Sequenom sued the company earlier this year, claiming that it infringes one of its patents. Last month, Sequenom asked the court for a preliminary injunction against Ariosa, barring it from using its test (CSN 2/29/2012).